Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 9:14 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 985–1008 of 1,869 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: First Treatment Period Clear all

Conditions: T Cell Lymphoma, T-cell Lymphoma
Interventions: Mogamulizumab, DA-EPOCH Protocol, CHOEP protocol; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 2
States / cities: New Haven, Connecticut • New York, New York

Conditions: Migraine
Interventions: Metformin, Matching Placebo; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 34 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2019
U.S. locations: 1
States / cities: Scottsdale, Arizona

Conditions: Hypoparathyroidism
Interventions: PCO371, Placebo; Drug
Lead sponsor: Chugai Pharmaceutical; Industry
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2021
U.S. locations: 8
States / cities: Torrance, California • Chicago, Illinois • Indianapolis, Indiana + 5 more

Conditions: COVID-19 Long Haul Syndrome
Interventions: Mind Body Syndrome Therapy for Long Covid; Behavioral
Lead sponsor: Beth Israel Deaconess Medical Center; Other
Eligibility: 18 Years to 60 Years
Enrollment: 23 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Schizophrenia
Interventions: armodafinil, placebo; Drug
Lead sponsor: Cephalon; Industry
Eligibility: 18 Years to 60 Years
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007
U.S. locations: 12
States / cities: Garden Grove, California • National City, California • Paramount, California + 9 more

Conditions: Breast Cancer
Interventions: GlowCap device; Other
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 60 Years and older · Female only
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: New York, New York

Conditions: Non Small Cell Lung Cancer
Interventions: DRP-104; Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 37 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 2
States / cities: New York, New York

Conditions: Venous Thromboembolism
Interventions: Atorvastatin, Anticoagulation Therapy; Drug
Lead sponsor: Ohio State University; Other
Eligibility: 18 Years and older
Enrollment: 21 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2020
U.S. locations: 1
States / cities: Columbus, Ohio

Conditions: Muscle Mass
Interventions: Strength Training, Wait first, then strength training; Behavioral · Other
Lead sponsor: Virginia Polytechnic Institute and State University; Other
Eligibility: 50 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Blacksburg, Virginia

Conditions: Brain Concussion, Neck Pain
Interventions: Cervical rehabilitation, Standard Concussion Care; Other
Lead sponsor: University of Pittsburgh; Other
Eligibility: 12 Years to 50 Years
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 2
States / cities: Pittsburgh, Pennsylvania • Milwaukee, Wisconsin

Conditions: NOMID, CINCA Syndrome
Interventions: Canakinumab; Drug
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 2 Years to 25 Years
Enrollment: 7 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Substance Use Disorder (SUD), Recovery
Interventions: EMA Only, EMI Only, EMA+EMI, Neither - RSAU; Other
Lead sponsor: Chestnut Health Systems; Other
Eligibility: 18 Years and older
Enrollment: 401 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2021
U.S. locations: 3
States / cities: Chicago, Illinois • Normal, Illinois

Conditions: Neoplasms
Interventions: GSK3368715; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years and older
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2021
U.S. locations: 5
States / cities: Los Angeles, California • Newport Beach, California • Philadelphia, Pennsylvania + 2 more

Conditions: Diabetic Peripheral Neuropathy
Interventions: Acupuncture; Procedure
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Non-Small-Cell Lung Carcinoma
Interventions: Cetuximab + platinum + gemcitabine, Platinum + Gemcitabine; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 31
States / cities: Mobile, Alabama • Anchorage, Alaska • Bakersfield, California + 28 more

Conditions: Urea Cycle Disorder
Interventions: RAVICTI, NaPBA; Drug
Lead sponsor: Amgen; Industry
Eligibility: Up to 99 Years
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2022
U.S. locations: 6
States / cities: Gainesville, Florida • New York, New York • Cleveland, Ohio + 3 more

Conditions: Fluid Overload, Heart Failure Acute
Interventions: Metolazone 60 minutes prior to furosemide, Metolazone concurrently with furosemide; Drug
Lead sponsor: University of Maryland, Baltimore; Other
Eligibility: 18 Years to 89 Years
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Sickle Cell Disease
Interventions: Alemtuzumab, low dose total body irradiation, Sirolimus; Drug
Lead sponsor: Robert Nickel; Other
Eligibility: 2 Years to 25 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2030
U.S. locations: 5
States / cities: Washington D.C., District of Columbia • Chicago, Illinois • New York, New York + 2 more

Conditions: Fibromyalgia, Musculoskeletal Pain
Interventions: S-Cone Stimulating Chromatic Light, Equal-Energy White Light; Device
Lead sponsor: University of North Carolina, Chapel Hill; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Clear-cell Renal Cell Carcinoma, RCC, Kidney Cancer, Clear-cell Kidney Carcinoma
Interventions: Avelumab, Sunitinib; Drug
Lead sponsor: Guru Sonpavde; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Brain Cancer
Interventions: PET scan, C-Choline; Device · Radiation
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Ectonucleotide Pyrophosphatase/phosphodiesterase1 Deficiency, Autosomal Recessive Hypophosphatemic Rickets, Generalized Arterial Calcification of Infancy
Interventions: INZ-701; Drug
Lead sponsor: Inozyme Pharma; Industry
Eligibility: 18 Years to 64 Years
Enrollment: 13 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2024
U.S. locations: 2
States / cities: Rochester, Minnesota • Eatontown, New Jersey

Conditions: Sleep Apnea, Obstructive, Patient Compliance
Interventions: Tailored, Usual care; Behavioral · Other
Lead sponsor: Milton S. Hershey Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 118 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2014
U.S. locations: 1
States / cities: Hershey, Pennsylvania

Conditions: Psoriatic Arthritis
Interventions: Placebo, Ixekizumab 80 mg Q4W, Ixekizumab 80 mg Q2W; Drug
Lead sponsor: Eli Lilly and Company; Industry
Eligibility: 18 Years and older
Enrollment: 363 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2019
U.S. locations: 59
States / cities: Birmingham, Alabama • Glendale, Arizona • Mesa, Arizona + 50 more

Search by objective public record fields.

Study of Mogamulizumab With DA-EPOCH or CHOEP in Patients With Aggressive T-cell Lymphoma

Metformin for the Prevention of Episodic Migraine (MPEM)

A Clinical Study Investigating the Safety, Tolerability, PK and PD of PCO371 in Patients With Hypoparathyroidism

Mind Body Intervention for COVID-19 Long Haul Syndrome

Efficacy and Safety of Armodafinil as Adjunctive Therapy in Schizophrenic Adults With Cognitive Deficits

GlowCap Reminder System in Patients With Early Stage Breast Cancer Receiving Adjuvant Endocrine Therapy

DRP-104 in Patients With NFE2L2/KEAP1-altered Non-Small Cell Lung Cancer

Statin Use in Patients With Acute VTE

Strength Training Response of Muscle in GLP-1 Users

Cervical Spine Focused Treatment for Patients With Persistent Concussion Symptoms and Neck Pain

Canakinumab to Treat Neonatal-Onset Multisystem Inflammatory Disease

Using Smartphones to Provide Recovery Support Services

First Time in Humans (FTIH) Study of GSK3368715 in Participants With Solid Tumors and Diffuse Large B-cell Lymphoma (DLBCL)

Group Acupuncture Treatment Effects for Painful Diabetic Neuropathy (GATE-PDN)

Study of Gemcitabine/Platinum +/- Cetuximab as First-Line Treatment for Patients With Advanced/Metastatic Non-Small Cell Lung Cancer

Study of Glycerol Phenylbutyrate & Sodium Phenylbutyrate in Phenylbutyrate Naïve Patients With Urea Cycle Disorders (UCDs)

Diuretic Effect of Metolazone Pre-dosing Versus Concurrent Dosing

Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease

Light Bulb Stimuli to Reduce Chronic Pain

Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma

Assessing 11C-Choline (11C-CH) PET to Distinguish True Tumor Progression From Pseudoprogression in High-grade Gliomas

Evaluation of Safety, Tolerability, and Efficacy of INZ-701 in Adults With ENPP1 Deficiency

Tailored Intervention to Promote Positive Airway Pressure Adherence

A Study of Ixekizumab (LY2439821) in Participants With Active Psoriatic Arthritis